16 completed, 5 terminated, 2 withdrawn, 1 active not recruiting. 25 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 25 | Completed 16, Terminated 5, Withdrawn 2, Active not recruiting 1, Unknown 1 |
| Phase 1 | 4 | Completed 2, Terminated 2 |
| Phase 3 | 1 | Completed 1 |
Follow Recurrent Non-Small Cell Lung Carcinoma: new trials by email Literature Review of Recurrent Non-Small Cell Lung Carcinoma trials Research Report on Recurrent Non-Small Cell Lung Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer Methotrexate, Pharmacokinetic Study, Regorafenib - KRAS Gene Mutation, Metastatic Malignant Neoplasm in the Brain | Phase 2 | Completed | Stanford University | 22 | 2018-08-14 | 2023-08-01 |
| Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads Nivolumab, Laboratory Biomarker Analysis - Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer | Phase 2 | Withdrawn | Vanderbilt-Ingram Cancer Center | 2017-12-29 | 2018-04-25 | |
| Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung Cancer Nivolumab - Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer | Phase 2 | Withdrawn | Emory University | 2017-07-21 | 2019-05-21 | |
| Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Metformin Hydrochloride, Nivolumab - Recurrent Non-Small Cell Lung Carcinoma, Stage III Non-Small Cell Lung Cancer | Phase 2 | Unknown | Northwestern University | 17 | 2017-07-12 | 2020-10-14 |
| Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer Nivolumab, Plinabulin - ALK Gene Translocation, EGFR Activating Mutation | Phase 1 / Phase 2 | Terminated | University of Washington | 5 | 2017-06-14 | 2019-03-04 |
| Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer 3-Dimensional Conformal Radiation Therapy (3D-CRT), Docetaxel, Gemcitabine - Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer | Phase 2 | Active not recruiting | NRG Oncology | 218 | 2017-04-07 | 2026-06-08 |
| Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations Chemotherapy, Immunotherapy, Laboratory Biomarker Analysis - EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma | Phase 2 | Terminated | Wake Forest University Health Sciences | 19 | 2017-03-10 | 2024-06-28 |
| Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 Laboratory Biomarker Analysis, Pembrolizumab, Recombinant EphB4-HSA Fusion Protein - ALK Gene Mutation, BRAF Gene Mutation | Phase 2 | Completed | University of Southern California | 42 | 2017-03-10 | 2025-10-22 |
| TG4010 and Nivolumab in Patients With Lung Cancer TG4010, Nivolumab - Recurrent Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer | Phase 2 | Completed | Megan Daly, MD | 13 | 2016-12-14 | 2025-11-10 |
| Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer Carboplatin, Laboratory Biomarker Analysis, Paclitaxel - Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer | Phase 2 | Completed | Wake Forest University Health Sciences | 43 | 2016-06-17 | 2024-01-05 |
| Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma Aldesleukin, Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes, Cyclophosphamide - Advanced Pleural Malignant Mesothelioma, HLA-A*0201 Positive Cells Present | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 11 | 2015-05-22 | 2021-09-13 |
| S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer Afatinib Dimaleate, Cetuximab, Laboratory Biomarker Analysis - Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer | Phase 2 / Phase 3 | Completed | SWOG Cancer Research Network | 174 | 2015-05-07 | 2026-05-18 |
| Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer Radiation Therapy, Carboplatin, Metformin - Adenosquamous Lung Carcinoma, Bronchioloalveolar Carcinoma | Phase 2 | Completed | NRG Oncology | 170 | 2014-08-01 | 2026-07-13 |
| Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer Auranofin, Sirolimus, Laboratory Biomarker Analysis - Extensive Stage Small Cell Lung Carcinoma, Lung Adenocarcinoma | Phase 1 / Phase 2 | Completed | Mayo Clinic | 29 | 2014-05-14 | 2025-09-05 |
| PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer Carboplatin, Computed Tomography, Intensity-Modulated Radiation Therapy - Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma | Phase 2 | Completed | Albert Einstein College of Medicine | 35 | 2013-07-01 | 2024-01-25 |
| Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer Cabozantinib S-malate, Erlotinib Hydrochloride, Laboratory Biomarker Analysis - Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7 | Phase 2 | Completed | National Cancer Institute (NCI) | 37 | 2013-05-20 | 2019-05-16 |
| Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer Azacitidine, Docetaxel, Entinostat - Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 17 | 2013-05-01 | 2018-07-27 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer Laboratory Biomarker Analysis, Paclitaxel Albumin-Stabilized Nanoparticle Formulation - Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer | Phase 2 | Completed | University of Washington | 26 | 2012-12-02 | 2021-07-16 |
| MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy Akt Inhibitor MK2206, Erlotinib Hydrochloride, Laboratory Biomarker Analysis - Adenosquamous Lung Carcinoma, Bronchioloalveolar Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 80 | 2011-02-01 | 2016-11-29 |
| Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer Bevacizumab, Carboplatin, Cixutumumab - Large Cell Lung Carcinoma, Lung Adenocarcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 175 | 2010-03-01 | 2018-06-06 |
Showing 20 of 25. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (25) · Adenocarcinoma of Lung (5) · Adenocarcinoma, Bronchiolo-Alveolar (3) · Brain Neoplasms (2) · Mesothelioma, Malignant (1) · Small Cell Lung Carcinoma (1) · Squamous Cell Carcinoma of Head and Neck (1)
Bronchial Neoplasms (25) · Carcinoma, Bronchogenic (25) · Lung Diseases (25) · Lung Neoplasms (25) · Neoplasms (25) · Neoplasms by Site (25) · Respiratory Tract Diseases (25) · Respiratory Tract Neoplasms (25) · Thoracic Neoplasms (25) · Neoplasms by Histologic Type (7) · Neoplasms, Glandular and Epithelial (7) · Carcinoma (6) · Adenocarcinoma (5) · Brain Diseases (2) · Central Nervous System Diseases (2)
Nivolumab (6) · Paclitaxel (5) · Carboplatin (4) · Erlotinib Hydrochloride (4) · Pemetrexed (4) · Taxes (4) · pembrolizumab (4) · Docetaxel (3) · Radiotherapy, Intensity-Modulated (3) · Azacitidine (2) · Gemcitabine (2) · Magnetic Resonance Spectroscopy (2) · Metformin (2) · Radiotherapy, Conformal (2) · entinostat (2)
National Cancer Institute (NCI) (7) · Albert Einstein College of Medicine (2) · NRG Oncology (2) · University of Washington (2) · Wake Forest University Health Sciences (2) · Emory University (1) · Fred Hutchinson Cancer Center (1) · Mayo Clinic (1) · Megan Daly, MD (1) · Northwestern University (1) · SWOG Cancer Research Network (1) · Stanford University (1) · University of Nebraska (1) · University of Southern California (1) · Vanderbilt-Ingram Cancer Center (1)
United States (24) · Canada (2) · Israel (2) · Saudi Arabia (1)
Apar K Ganti, MD (1) · Christina Baik (1) · Douglas Johnson, M.D. (1) · Heather Wakelee (1) · John Wrangle (1) · Jorge Nieva, MD (1) · Julie Brahmer (1) · Karen Kelly (1) · Karen Reckamp (1) · Nitin Ohri (1) · Primo Lara (1) · Puneeth Iyengar (1) · Rafael Santana-Davila (1) · Rathi Pillai, MD (1)
PMID 22586682, PMID 27491498, PMID 28950351, PMID 30915273, PMID 33021871, PMID 33608212, PMID 34323922, PMID 35254001, PMID 41114938
P30CA006973 (3), P30CA015704 (3), N01CM00038 (2), P30CA012197 (2), P30CA013330 (2), P30CA033572 (2), U10CA180868 (2), N01CM00070 (1), N01CM00071 (1), N01CM62209 (1), P30CA014089 (1), P30CA036727 (1), P30CA060553 (1), P30CA093373 (1), R21CA153000 (1)